TSE:4503Pharmaceuticals
A Look At Astellas Pharma (TSE:4503) Valuation After Positive PADCEV Plus Keytruda Phase 3 Data
Positive Phase 3 data for PADCEV plus Keytruda in muscle invasive bladder cancer has put Astellas Pharma (TSE:4503) in focus, as investors weigh what the EV-304 results could mean for its oncology franchise.
See our latest analysis for Astellas Pharma.
The positive EV-304 update lands after a 19.78% 90 day share price return and a 12.86% year to date share price return, alongside a 73.33% 1 year total shareholder return that points to strong ongoing momentum.
If this oncology news has you...